We are live on ! Find out more
INM icon

InMed Pharmaceuticals
INM

11 hedge funds and large institutions have $877K invested in InMed Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 2 increasing their positions, 0 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,250% more capital invested

Capital invested by funds: $65K → $877K (+$812K)

0.91% more ownership

Funds ownership: 0.01% → 0.92% (+0.91%)

0% more funds holding

Funds holding: 11 → 11 (0)

0% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 6

Holders
11
Holders Change
–
Holders Change %
0%
% of All Funds
0.19%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
2
Reduced
–
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
+$479K
2
SM
Sabby Management
Florida
+$141K
3
Millennium Management
Millennium Management
New York
+$129K
4
Bank of America
Bank of America
North Carolina
+$62.7K
5
UBS Group
UBS Group
Switzerland
+$53.6K

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$23K
2
Two Sigma Advisers
Two Sigma Advisers
New York
-$23K
3
Citadel Advisors
Citadel Advisors
Florida
-$6K
4
Geode Capital Management
Geode Capital Management
Massachusetts
-$6K
5
Creative Planning
Creative Planning
Kansas
-$5K
Name Holding Trade Value Shares
Change 		Change in
Stake
AC
1
Armistice Capital
New York
$593K +$479K +2,588 +135%
SM
2
Sabby Management
Florida
$101K +$141K +764 New
Millennium Management
3
Millennium Management
New York
$91K +$129K +696 New
Bank of America
4
Bank of America
North Carolina
$45K +$62.7K +339 New
UBS Group
5
UBS Group
Switzerland
$38K +$53.6K +290 New
TRCT
6
Tower Research Capital (TRC)
New York
$7K +$9.8K +53 New
Morgan Stanley
7
Morgan Stanley
New York
$1K +$1.29K +7 New
TWC
8
TD Waterhouse Canada
Ontario, Canada
$757 – – –
FDCDDQ
9
Federation des caisses Desjardins du Quebec
Quebec, Canada
$125 – – –
Renaissance Technologies
10
Renaissance Technologies
New York
– -$23K -99 Closed
Two Sigma Advisers
11
Two Sigma Advisers
New York
– -$23K -97 Closed
Geode Capital Management
12
Geode Capital Management
Massachusetts
– -$6K -28 Closed
Citadel Advisors
13
Citadel Advisors
Florida
– -$6K -26 Closed
Creative Planning
14
Creative Planning
Kansas
– -$5K -22 Closed
Royal Bank of Canada
15
Royal Bank of Canada
Ontario, Canada
– -$185 -1 Closed
Osaic Holdings
16
Osaic Holdings
Arizona
– +$370 +2 +100%

INM Hedge Fund Activity: Q3 2022 in Review

11 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in InMed Pharmaceuticals (INM) for Q3 2022, worth a combined $877K — up 1,250% from $65K a quarter earlier.

Fund positioning in INM was balanced in Q3 2022: 6 funds opened new positions, 6 closed out, 2 added to existing stakes and 0 trimmed.

The largest buyer was Armistice Capital, adding an estimated $479K. The largest seller was Renaissance Technologies, exiting entirely with an estimated $23K sold.

  • 11 institutional investors held InMed Pharmaceuticals (INM) as of Q3 2022, unchanged from Q2 2022.
  • Funds reported $877K of InMed Pharmaceuticals stock for Q3 2022, up 1,250% quarter-over-quarter.
  • 6 funds opened new InMed Pharmaceuticals positions in Q3 2022 and 6 closed out, a net change of 0 holders.
  • The largest InMed Pharmaceuticals buyer in Q3 2022 was Armistice Capital, an estimated $479K added.
  • The largest InMed Pharmaceuticals seller in Q3 2022 was Renaissance Technologies, an estimated $23K sold.

Based on aggregated 13F filings for Q3 2022.